F Eduati, P Jaaks, J Wappler, T Cramer… - Molecular systems …, 2020 - embopress.org
Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating …
Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer and are responsible for imparting differential drug responses in cancer patients. Recently …
Although genetically engineered mouse (GEM) models are often used to evaluate cancer therapies, extrapolation of such preclinical data to human cancer can be challenging. Here …
Making decisions on how best to treat cancer patients requires the integration of different data sets, including genomic profiles, tumour histopathology, radiological images, proteomic …
AA Shafi, MJ Schiewer, R de Leeuw, E Dylgjeri… - European urology …, 2018 - Elsevier
Background Androgen deprivation therapy is a first-line treatment for disseminated prostate cancer (PCa). However, virtually all tumors become resistant and recur as castration …
F Fröhlich, T Kessler, D Weindl, A Shadrin… - Cell systems, 2018 - cell.com
Mechanistic models are essential to deepen the understanding of complex diseases at the molecular level. Nowadays, high-throughput molecular and phenotypic characterizations …
The ability to rapidly assess the efficacy of therapeutic strategies for incurable bone metastatic prostate cancer is an urgent need. Pre-clinical in vivo models are limited in their …
Recent advances in pharmacogenomics have generated a wealth of data of different types whose analysis have helped in the identification of signatures of different cellular …
R Coletti, L Leonardelli, S Parolo, L Marchetti - Scientific reports, 2020 - nature.com
Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing promising results for the treatment of numerous cancers refractory to conventional therapies …